



COPHy 2024 – FINAL SCIENTIFIC PROGRAM

FRIDAY, MARCH 15, 2024		
08:30-10:00	BIG CONTROVERSIES IN RETINA IN 2024	HALL A
Chairs:	<u>Baruch Kuppermann</u> , USA; <u>Anat Loewenstein</u> , Israel; <u>Stratos Gotzaridis</u> , Greece; <u>George Charonis</u> , Greece	
08:30-08:40	Welcome Remarks <u>Baruch Kuppermann</u> , USA; <u>Anat Loewenstein</u> , Israel; <u>Stratos Gotzaridis</u> , Greece	
08:40-09:00	Keynote Lecture: How good are we really without Artificial Intelligence (AI) tools <u>Ursula Schmidt-Erfurth</u> , Austria	
08:40-08:55		
08:55-09:00	Q&A	
09:00-09:30	Debate 1: Is AI ready to replace physicians?	
09:00-09:10	Yes: <u>Guisepppe Querques</u> , Italy	
09:10-09:20	No: <u>Paolo Lanzetta</u> , Italy	
09:20-09:30	Discussion	
09:30-10:00	Debate 2: Intraocular inflammation is a major risk factor which should impede us from using anti complement agents for Geographic atrophy	
09:30-09:40	Yes: <u>Dinah Zur</u> , Israel	
09:40-09:50	No: <u>Jordi Monés</u> , Spain	
09:50-10:00	Discussion	
10:00-10:30	Coffee Break, Visit Exhibition, View ePosters & join us in the Speakers' Corner	EXHIBITION AREA



FRIDAY, MARCH 15, 2024			
HALL A		HALL B	
10:30-12:00	MEDICAL RETINA 1 Neovascular (“Wet”) AMD Management	10:30-12:00	GLAUCOMA 1
Chairs:	<u>Baruch Kuppermann</u>, USA; <u>Reinier Schlingemann</u>, Netherlands	Chairs:	<u>Francesca Cordeiro</u>, UK; <u>George Mangouritsas</u>, Greece
10:30-11:00	Debate 1: New generation molecules as first-line treatment in neovascular AMD	10:30-11:00	Debate 1: SLT – first-line or second-line?
10:30-10:40	Yes: <u>John W. Kitchens</u> , USA	10:30-10:40	Yes: <u>Dimitrios Besinis</u> , Greece
10:40-10:50	No: <u>Reinier Schlingemann</u> , Netherlands	10:40-10:50	No: <u>Ioannis Halkiadakis</u> , Greece
10:50-11:00	Discussion	10:50-11:00	Discussion
11:00-11:30	Debate 2: We are already in the era of personalized treatment strategies	11:00-11:30	Debate 2: IOP assessment – Are Diurnal measurements better than alternatives e.g. Water Drinking Test?
11:00-11:10	Yes: <u>Stela Vujosevic</u> , Italy	11:00-11:10	Yes: <u>John Danias</u> , USA
11:10-11:20	No: <u>Tryfon Rotsos</u> , Greece	11:10-11:20	No: <u>Ioannis Halkiadakis</u> , Greece
11:20-11:30	Discussion	11:20-11:30	Discussion
11:30-12:00	Debate 3: Durability associated with multi target therapies is superior to anti-VEGF mono-target therapy in AMD	11:30-12:00	Debate 3: NTG – Is this a separate disease from POAG?
11:30-11:40	Yes: <u>Irini Chatziralli</u> , Greece	11:30-11:40	Yes: <u>John Danias</u> , USA
11:40-11:50	No: <u>Reinier Schlingemann</u> , Netherlands	11:40-11:50	No: <u>Francesca Cordeiro</u> , UK
11:50-12:00	Discussion	11:50-12:00	Discussion
12:15-13:15	Industry Sponsored Luncheon Symposium (Lunch boxes served 12:00-12:15)	HALL A	
13:15-13:45	Coffee Break, Visit Exhibition, View ePosters & join us in the Speakers’ Corner	EXHIBITION AREA	



FRIDAY, MARCH 15, 2024			
HALL A		HALL B	
13:45-15:15	SURGICAL RETINA 1 Controversial Approaches to Common Surgical Questions	13:45-15:15	GLAUCOMA 2
Chairs:	<u>William F. Mieler</u> , USA; <u>Stanislao Rizzo</u> , Italy, <u>Stratos Gotzaridis</u> , Greece	Chairs:	<u>Francesca Cordeiro</u> , UK; <u>Petros Smahliou</u> , Greece;
13:45-14:15	Debate 1: Vitrectomy is safe and effective in the management of visually significant floaters (myodesopsia)	13:45-14:15	Debate 1: MIGS - first-line or second-line?
13:45-13:55	Yes: <u>Petros Petrou</u> , Greece	13:45-13:55	Yes: <u>Ioanna Tryfinopoulou</u> , Greece
13:55-14:05	No: <u>William F. Mieler</u> , USA	13:55-14:05	No: <u>Dimitrios Besinis</u> , Greece
14:05-14:15	Discussion	14:05-14:15	Discussion
14:15-14:45	Debate 2: In epiretinal membrane (ERM) surgery, removal of the internal limiting membrane (ILM) is essential to improve vision and limit recurrences	14:15-14:45	Debate 2: MIGS – Should all devices have corneal endothelial cell counts?
14:15-14:25	Yes: <u>Francesco Boscia</u> , Italy	14:15-14:25	Yes: <u>Stelios Kandarakis</u> , Greece
14:25-14:35	No: <u>William F. Mieler</u> , USA	14:25-14:35	No: <u>George Mangouritsas</u> , Greece
14:35-14:45	Discussion	14:35-14:45	Discussion
14:45-15:15	Debate 3: Treatment of recurrent macular hole should include the use of a free ILM flap or other intraoperative surgical adjuvants	14:45-15:15	Debate 3: Neuroprotection – can we really measure it in glaucoma?
14:45-14:55	Yes: <u>Orit Vidne</u> , Israel	14:45-14:55	Yes: <u>Francesca Cordeiro</u> , UK
14:55-15:05	No: <u>Stanislao Rizzo</u> , Italy	14:55-15:05	No: <u>George Mangouritsas</u> , Greece
15:05-15:15	Discussion	15:05-15:15	Discussion



FRIDAY, MARCH 15, 2024		
15:15-16:15	VISION ACADEMY IN RETINA 2024 Artificial intelligence in retinal disease management: evolution or revolution?	HALL A
Chairs:	<u>Anat Loewenstein</u> , Israel <u>Baruch Kuppermann</u> , USA	
15:15-15:20	Introduction to the Vision Academy <u>Anat Loewenstein</u> , Israel	
15:20-15:30	AI in retinal disease screening and diagnosis – introduction to current and future options <u>Paolo Lanzetta</u> , Italy	
15:30-15:40	AI in retinal disease management –introduction to current and future options <u>Tariq Aslam</u> , UK	
15:40-15:45	Q&A Moderated by: <u>Baruch Kuppermann</u> , USA	
15:45-16:15	Panel discussion / Audience Q&A Considerations for implementing AI solutions in clinical practice – impact on patients and HCPs Moderators: <u>Anat Loewenstein</u> , Israel; <u>Baruch Kuppermann</u> , USA Panelists: <u>Dinah Zur</u> , Israel <u>Paolo Lanzetta</u> , Italy <u>Tariq Aslam</u> , UK <u>Javier Zarranz-Ventura</u> , Spain Session Close: <u>Anat Loewenstein</u> , Israel; <u>Baruch Kuppermann</u> , USA	
16:15-17:15	"Happy Hour" Cocktail	EXHIBITION AREA
End of Day		



SATURDAY, MARCH 16, 2024			
HALL A		HALL B	
08:30-10:00	MEDICAL RETINA 2 Diabetic Macular Edema (DME) and Proliferative Diabetic Retinopathy	08:30-10:00	NEURO-OPHTHALMOLOGY 1 The Afferent Pathway
Chairs:	Francesco Bandello , Italy; Irini Chatziralli , Greece	Chairs:	Andrew G. Lee , USA
08:30-09:00	Debate 1: Oral drugs have the potential to be beneficial for halting the progression of NPDR	08:30-09:00	Debate 1: Should all elderly patients with acute visual loss go to the ER for stroke evaluation and treatment?
08:30-08:40	Yes: Francesco Bandello , Italy	08:30-08:40	Yes: John Chen , USA
08:40-08:50	No: Dinah Zur , Israel	08:40-08:50	No: Susan Mollan , UK
08:50-09:00	Discussion	08:50-09:00	Discussion
09:00-09:30	Debate 2: Are regular anti-VEGF injections beneficial for long term management of diabetic retinopathy?	09:00-09:30	Debate 2: Patients with visual snow syndrome should undergo work up and treatment?
09:00-09:10	Yes: Francesco Bandello , Italy	09:00-09:10	Yes: Eleni Papageorgiou , Greece
09:10-09:20	No: Michaella Goldstein , Israel	09:10-09:20	No: Andrew G. Lee , USA
09:20-09:30	Discussion	09:20-09:30	Discussion
09:30-10:00	Debate 3: Is high dose anti-VEGF monotherapy superior to regular dose anti-VEGF monotherapy for DME	09:30-10:00	Case Presentations
09:30-09:40	Yes: Anat Loewenstein , Israel		<i>Moderator: John Chen, USA</i>
09:40-09:50	No: Michaella Goldstein , Israel		<i>Panelists: All Speakers</i>
09:50-10:00	Discussion		
10:00-10:30	Coffee Break, Visit Exhibition, View ePosters & join us in the Speakers' Corner		EXHIBITION AREA



SATURDAY, MARCH 16, 2024			
	HALL A		HALL B
10:30-12:00	MEDICAL RETINA 3 AMD and Hereditary Retinal Degeneration Topics	10:30-12:00	UVEITIS 1
Chairs:	Tryfon Rotsos , Greece; Miltiadis Tsilimbaris , Greece; Baruch Kuppermann , USA	Chairs:	Bahram Bodaghi , France; Sofia Androudi , Greece
10:30-11:00	Debate 1: Complement inhibition is generally recommended for patients with geographic atrophy	10:30-11:00	Debate 1: Multifocal lenses in uveitic cataract
10:30-10:40	Yes: Ursula Schmidt-Erfurth , Austria	10:30-10:40	Yes: Aniruddha Agarwal , UAE
10:40-10:50	No: Tariq Aslam , UK	10:40-10:50	No: Bahram Bodaghi , France
10:50-11:00	Discussion	10:50-11:00	Discussion
11:00-11:30	Debate 2: Gene therapy is the new era of treating retinal diseases	11:00-11:30	Debate 2: The use of biosimilar drugs in uveitis
11:00-11:10	Yes: Hendrik Scholl , Switzerland	11:00-11:10	Yes: Sarah Touhami , France
11:10-11:20	No: John W. Kitchens , USA	11:10-11:20	No: Sofia Androudi , Greece
11:20-11:30	Discussion	11:20-11:30	Discussion
11:30-12:00	Debate 3: Biosimilars are equivalent to established Anti-VEGF agents to treat neovascular AMD	11:30-12:00	Debate 3: OCT-Angiography is a Must-Have Tool for the Management of White Dot Syndromes
11:30-11:40	Yes: Baruch Kuppermann , USA	11:30-11:40	Yes: Bahram Bodaghi , France
11:40-11:50	No: Javier Zarranz-Ventura , Spain	11:40-11:50	No: Aniruddha Agarwal , UAE
11:50-12:00	Discussion	11:50-12:00	Discussion
12:15-13:15	Industry-Sponsored Luncheon Symposium <i>(Lunch boxes served 12:00-12:15)</i>		HALL A
13:30-14:30	Industry-Sponsored Dessert Symposium <i>(Dessert boxes served 13:15-13:30)</i>		HALL A
14:30-15:00	Coffee Break, Visit Exhibition, View ePosters & join us in the Speakers' Corner		EXHIBITION AREA



SATURDAY, MARCH 16, 2024			
HALL A		HALL B	
15:00-16:30	SURGICAL RETINA 2 Controversies in the Utilization of Cutting Edge Vitreoretinal Surgical Technology	15:00-16:30	NEURO-OPHTHALMOLOGY 2 The Efferent Pathway
Chairs:	Efstratios Paroikakis , Greece, Jose Maria Ruiz-Moreno , Spain, William F. Mieler , USA	Chairs:	Andrew G. Lee , USA
15:00-15:30	Debate 1: The use of the heads up, digital imaging operating microscope, has led to significant visual and anatomic improvement in surgical outcomes	15:00-15:30	Debate 1: Should all patients with myasthenia gravis be offered thymectomy?
15:00-15:10	Yes: Stratos Gotzaridis , Greece	15:00-15:10	Yes: John Chen , USA
15:10-15:20	No: William F. Mieler , USA	15:10-15:20	No: Eleni Papageorgiou , Greece
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Debate 2: Surgical intraoperative OCT is essential for best anatomic outcomes in macular surgery	15:30-16:00	Debate 2: Should all patients with idiopathic intracranial hypertension (IIH) have an LP?
15:30-15:40	Yes: Efstratios Paroikakis , Greece	15:30-15:40	Yes: Susan Mollan , UK
15:40-15:50	No: Jose Maria Ruiz-Moreno , Spain	15:40-15:50	No: Andrew G. Lee , USA
15:50-16:00	Discussion	15:50-16:00	Discussion
16:00-16:30	Debate 3: The use of intravitreal methotrexate in the management of RD with significant PVR leads to better anatomic and visual outcomes	16:00-16:30	Case Presentations
16:00-16:10	Yes: Theodoros Giannopoulos , Greece		<i>Moderator: John Chen, USA</i>
16:10-16:20	No: Francesco Boscia , Italy		<i>Panelists: All Speakers</i>
16:20-16:30	Discussion		



SATURDAY, MARCH 16, 2024			
HALL A		HALL B	
16:30-18:00	MEDICAL RETINA 4 New Treatment Strategies	16:30-18:00	UVEITIS 2
Chairs:	<u>Baruch Kuppermann</u> , USA; <u>Jordi Monés</u> , Spain	Chairs:	<u>Bahram Bodaghi</u> , France; <u>Aniruddha Agarwal</u> , UAE
16:30-17:00	Debate 1: The role of biosimilars will remain important even with many new non-biosimilar drug options becoming available	16:30-17:00	Debate 1: Prophylactic laser photocoagulation and vitrectomy for ARN
16:30-16:40	Yes: <u>Stela Vujosevic</u> , Italy	16:30-16:40	Yes: <u>Marilita Moschos</u> , Greece
16:40-16:50	No: <u>Sobha Sivaprasad</u> , UK	16:40-16:50	No: <u>Sarah Touhami</u> , France
16:50-17:00	Discussion	16:50-17:00	Discussion
17:00-17:30	Debate 2: Genetic treatment has the potential to change the outcome of AMD patients	17:00-17:30	Debate 2: Topical prostaglandins can be given in eyes with uveitis
17:00-17:10	Yes: <u>Hendrik Scholl</u> , Switzerland	17:00-17:10	Yes: <u>Sarah Touhami</u> , France
17:10-17:20	No: <u>Sobha Sivaprasad</u> , UK	17:10-17:20	No: <u>Sofia Androudi</u> , Greece
17:20-17:30	Discussion	17:20-17:30	Discussion
17:30-18:00	Debate 3: Are OCT parameters better than visual acuity in determining the benefit of new dry AMD agents?	17:30-18:00	Debate 3: Glaucoma tube shunts are better than trabeculectomy for uveitic glaucoma
17:30-17:40	Yes: <u>Guisepppe Querques</u> , Italy	17:30-17:40	Yes: <u>Marilita Moschos</u> , Greece
17:40-17:50	No: <u>Jordi Monés</u> , Spain	17:40-17:50	No: <u>Aniruddha Agarwal</u> , UAE
17:50-18:00	Discussion	17:50-18:00	Discussion
End of Congress		End of Congress	